Trial Profile
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Gallium 68 RM2 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 18 Nov 2023 Status changed from active, no longer recruiting to completed.
- 14 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Dec 2020 Status changed from suspended to recruiting.